Vestal Point Capital LP increased its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 151.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,230,000 shares of the company's stock after purchasing an additional 740,000 shares during the period. Vestal Point Capital LP owned 2.25% of Voyager Therapeutics worth $6,974,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC purchased a new stake in Voyager Therapeutics during the 4th quarter worth $29,000. Tower Research Capital LLC TRC boosted its position in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after purchasing an additional 2,444 shares during the period. Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics during the 4th quarter worth $60,000. Finally, Tema Etfs LLC purchased a new position in Voyager Therapeutics in the 4th quarter valued at about $85,000. 48.03% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
VYGR has been the subject of a number of analyst reports. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Canaccord Genuity Group decreased their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $13.39.
View Our Latest Stock Report on VYGR
Insider Activity
In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.39% of the company's stock.
Voyager Therapeutics Stock Performance
Shares of Voyager Therapeutics stock traded down $0.07 during trading on Friday, reaching $2.92. The company had a trading volume of 306,830 shares, compared to its average volume of 441,445. The company has a market cap of $161.58 million, a price-to-earnings ratio of 4.11 and a beta of 0.95. The firm's fifty day moving average is $3.36 and its 200-day moving average is $4.69. Voyager Therapeutics, Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $9.55.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. On average, research analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Voyager Therapeutics Company Profile
(
Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
